Systems and methods for anchoring and sealing a prosthetic heart valve

Description

FIELD OF THE DISCLOSURE

The present disclosure relates generally to prosthetic heart valves and methods for replacing diseased or defective native heart valves, and more particularly to an expandable prosthetic heart valve including features for anchoring and sealing the prosthetic heart valve onto a native human heart and related methods for implanting the prosthetic heart valve to replace a diseased or defective native heart valve.

BACKGROUND OF THE DISCLOSURE

Various types of prosthetic heart valves are commonly used in valve replacement surgery to replace a diseased or defective native heart valve, such as an aortic valve, a mitral valve, a pulmonary valve, or a tricuspid valve, of a native human heart. A prosthetic heart valve generally may include a frame or other support structure configured for positioning at an implantation site at or near the native heart valve and anchoring onto the native heart, and an occluder member, such as a multi-leaflet valve, attached to the frame and configured for controlling blood flow through the prosthetic heart valve. Upon implantation of the prosthetic heart valve, the frame may maintain the relative position of the prosthetic heart valve within the native heart, and the occluder member may control blood flow in a manner similar to the native heart valve, thereby restoring desired function of the heart.

According to traditional procedures, heart valve replacement may be performed via open heart surgery, which may require cardiopulmonary bypass and may present a significant risk of certain complications. In recent years, less-invasive procedures for heart valve replacement have been developed, which may eliminate the need for cardiopulmonary bypass and may decrease the risk of complications as compared to open heart surgery. For example, certain prosthetic heart valves may be implanted via a transapical approach, a transatrial approach, a transfemoral approach, a transseptal approach, a subclavian approach, a direct aortic puncture approach, or other vascular access approaches. Each type of approach for implanting prosthetic heart valves may present certain benefits and drawbacks. For example, the transapical approach may provide a direct, “straight shot” approach for replacing certain native heart valves, may allow a physician to leverage past experience in performing transcatheter aortic valve replacement (TAVR) procedures, and may allow a physician to have high degree of control over the prosthetic heart valve and instruments used to implant the heart valve. However, the transapical approach may be challenging in certain patients due to poor tissue quality at the apex of the heart and/or a relatively large outer diameter of the prosthetic heart valve being implanted, may result in left ventricle dysfunction, may present issues of sub-valvular entanglement, and may be more invasive than other potential approaches.

The transatrial approach may provide a direct antegrade approach for replacing certain native heart valves, may avoid sub-valvular anatomy, may eliminate the need to puncture the left ventricle, and may be less sensitive to the size of the outer diameter of the prosthetic heart valve being implanted. However, the transatrial approach may present challenges in steering and navigating the prosthetic heart valve through the anatomy to the desired implantation site, may present a steep learning curve for a physician having experience only with the transapical approach, and may be more invasive than other potential approaches. The transseptal approach may provide a direct antegrade approach for replacing certain native heart valves, may eliminate the need to puncture the left ventricle, and may allow a physician to leverage past experience in performing other procedures through a transseptal puncture. However, the transseptal approach may present challenges in steering and navigating the prosthetic heart valve through the anatomy to the desired implantation site, may require a physician to deliver the prosthetic heart valve over a relatively long distance as compared to other potential approaches, may present challenges in patients having an atrial and/or septal defect, in particular when the prosthetic heart valve has a relatively large outer diameter, and may require venous or arterial access in order to deliver the prosthetic heart valve to the desired implantation site.

Currently, less-invasive approaches are most commonly used in performing aortic valve replacement procedures, although it would be desirable to use less-invasive approaches in replacing mitral valves, pulmonary valves, and/or tricuspid valves in a similar manner. In view of the differences between the aortic valve and the other native heart valves, however, prosthetic heart valves and related instruments configured for aortic valve replacement generally would not be suitable for replacing the other native heart valves. Accordingly, there remains a need for a prosthetic heart valve that is suitable for replacement of the mitral valve, the pulmonary valve, and/or the tricuspid valve. It will be appreciated that a prosthetic heart valve configured for mitral, pulmonary, and/or tricuspid valve replacement may require certain differences in design and function, as compared to prosthetic heart valves configured for aortic valve replacement, in order to be implanted via a less-invasive approach and to function in a suitable manner. In particular, such a prosthetic heart valve should accommodate or conform to the shape and structure of the native heart valve and/or surrounding anatomy without compromising the integrity or function of the surrounding anatomy or the occluder member of the prosthetic heart valve. Such a prosthetic heart valve also should securely anchor onto the native heart tissue to prevent or inhibit migration of the prosthetic heart valve from the implantation site. Further, such a prosthetic heart valve should form a seal against the native heart tissue to prevent or inhibit paravalvular leakage.

SUMMARY OF THE DISCLOSURE

Various embodiments described herein provide prosthetic heart valves and related methods for implanting a prosthetic heart valve to replace a diseased or defective native heart valve. According to one aspect, a prosthetic heart valve for replacing a diseased or defective native heart valve is provided. In one embodiment, the prosthetic heart valve may include an outer frame, an inner frame positioned at least partially within the outer frame, and an occluder member positioned at least partially within the inner frame. The prosthetic heart valve also may include an atrial flange extending from an atrial end of the outer frame, and a ventricular flange extending from a ventricular end of the outer frame, wherein at least a portion of the atrial flange extends radially outward beyond the ventricular flange.

In another embodiment, the prosthetic heart valve may include an outer frame having a D-shaped cross-sectional shape in a plane orthogonal to a longitudinal axis of the prosthetic heart valve, and an inner frame positioned at least partially within the outer frame and having a circular cross-sectional shape in the plane orthogonal to the longitudinal axis of the prosthetic heart valve. The prosthetic heart valve also may include an occluder member positioned at least partially within the inner frame, an atrial flange extending from an atrial end of the outer frame, and a ventricular flange extending from a ventricular end of the outer frame.

In still another embodiment, the prosthetic heart valve may include an expandable outer frame having a D-shaped cross-sectional shape in a plane orthogonal to a longitudinal axis of the prosthetic heart valve, and an expandable inner frame positioned at least partially within the outer frame and having a circular cross-sectional shape in the plane orthogonal to the longitudinal axis of the prosthetic heart valve. The prosthetic heart valve also may include an occluder member positioned at least partially within the inner frame, an atrial flange extending from an atrial end of the outer frame, and a ventricular flange extending from a ventricular end of the outer frame, wherein at least a portion of the atrial flange extends radially outward beyond the ventricular flange.

These and other aspects and embodiments of the present disclosure will be apparent or will become apparent to one of ordinary skill in the art upon review of the following detailed description when taken in conjunction with the several drawings and the appended claims.

BRIEF DESCRIPTION OF THE DRAWINGS

In describing the various embodiments of the present disclosure, reference is made to the accompanying drawings, which are not necessarily drawn to scale, and wherein:

FIG. 1A is a side view of a prosthetic heart valve and a portion of a delivery device in accordance with one or more embodiments of the present disclosure, showing the prosthetic heart valve in an expanded state.

FIG. 1B is a side view of an outer frame, an inner frame, an atrial flange/skirt, and a ventricular flange/skirt of the prosthetic heart valve and a portion of the delivery device of FIG. 1A, showing the prosthetic heart valve in the expanded state.

FIG. 1C is a top perspective view of the prosthetic heart valve and a portion of the delivery device of FIG. 1A, showing the prosthetic heart valve in the expanded state.

FIG. 1D is a top perspective view of the outer frame, the inner frame, the atrial flange/skirt, and the ventricular flange/skirt of the prosthetic heart valve and a portion of the delivery device of FIG. 1A, showing the prosthetic heart valve in the expanded state.

FIG. 1E is a bottom perspective view of the prosthetic heart valve and a portion of the delivery device of FIG. 1A, showing the prosthetic heart valve in the expanded state.

FIG. 1F is a bottom perspective view of the outer frame, the inner frame, the atrial flange/skirt, and the ventricular flange/skirt of the prosthetic heart valve and a portion of the delivery device of FIG. 1A, showing the prosthetic heart valve in the expanded state.

FIG. 2A is a side view of a prosthetic heart valve in accordance with one or more embodiments of the present disclosure, showing the prosthetic heart valve in an expanded state.

FIG. 2B is a top view of the prosthetic heart valve of FIG. 2A, showing the prosthetic heart valve in the expanded state.

FIG. 2C is a bottom view of the prosthetic heart valve of FIG. 2A, showing the prosthetic heart valve in the expanded state.

FIG. 2D is a side view of an outer frame, an atrial flange/skirt, and a ventricular flange/skirt of the prosthetic heart valve of FIG. 2A, showing the outer frame, the atrial flange/skirt, and the ventricular flange/skirt in the expanded state.

FIG. 2E is a perspective view of a portion of the prosthetic heart valve of FIG. 2A and a portion of a delivery device attached to the prosthetic heart valve, showing the prosthetic heart valve in the expanded state and an anchor of the prosthetic heart valve in a deployed state.

FIG. 2F is a detailed side view of a portion of the prosthetic heart valve of FIG. 2A, showing the anchor of the prosthetic heart valve in the deployed state.

FIG. 2G is a bottom perspective view of the outer frame of the prosthetic heart valve of FIG. 2A and a portion of the delivery device, showing the outer frame in the expanded state.

FIG. 2H is a detailed side view of a portion of the prosthetic heart valve of FIG. 2A and a portion of the delivery device, showing a petal of the atrial flange/skirt of the prosthetic heart valve in a collapsed state.

FIG. 2I is a detailed side view of a portion of the prosthetic heart valve of FIG. 2A, showing petals of the atrial flange/skirt in an expanded state.

FIG. 2J is a partial cross-sectional side view of the prosthetic heart valve of FIG. 2A positioned within a native mitral valve of a native human heart, showing the outer frame and the atrial flange/skirt of the prosthetic heart valve in a collapsed state and the ventricular flange/skirt in an expanded state.

FIG. 3A is a side view of a sheathed prosthetic heart valve, beginning a series in FIGS. 3A-3F showing a computer-assisted mitral valve replacement of the invention.

FIG. 3B is a side view of the prosthetic heart valve of FIG. 3A showing unsheathing of the ventricular skirt.

FIG. 3C is a composite top view, a side view and a computer generated positioning top view of the prosthetic heart valve of FIG. 3A showing controlled expansion of the frame, allowing repositioning or re-sheathing by contracting the frame.

FIG. 3D is a top view of the prosthetic heart valve of FIG. 3A showing the atrial petals open for positioning and hemodynamic function verification.

FIG. 3E is a composite of a top perspective view and a top view of the prosthetic heart valve of FIG. 3A showing release of the control wires in the final position.

FIG. 3F is a composite top view and a bottom view of the prosthetic heart valve of FIG. 3A showing removing the guide wire and final verification of the valve position and function.

FIG. 3G is a top view of a prosthetic heart valve, beginning a series in FIGS. 3G-3L, showing how a single articulating operation minimizes complexity in re-sheathing atrial petals after deployment.

FIG. 3H is a bottom perspective view of the prosthetic heart valve of FIG. 3G showing how control wires pass outside or within slots in atrial petals to enable inward deflection.

FIG. 3I is a bottom perspective view of the prosthetic heart valve of FIG. 3G showing coordinated contraction of stent and forward motion of sheath to allow for petals to be retracted into the frame.

FIG. 3J is a side view of the prosthetic heart valve of FIG. 3G showing contraction and re-sheathing.

FIG. 3K is a side view of the prosthetic heart valve of FIG. 3G showing that the structure from a multi-lumen tube allows the use of wires to pull petals inward without damaging the tip.

FIG. 3L is a side view of the prosthetic heart valve of FIG. 3G showing the tip recoiling into a straight configuration after passing over the implant.

DETAILED DESCRIPTION OF THE DISCLOSURE

Various embodiments of the present disclosure provide improved expandable prosthetic heart valves, delivery devices, and methods for replacing diseased or defective native heart valves. Such expandable prosthetic heart valves, delivery devices, and methods may address one or more of the above-described drawbacks of existing technology for heart valve replacement. As described below, the expandable prosthetic heart valves, delivery devices, and methods provided herein may be configured for mitral valve replacement, although the expandable prosthetic heart valves, delivery devices and methods alternatively may be configured for aortic, pulmonary, or tricuspid valve replacement.

Embodiments of the present disclosure are described herein below with reference to the accompanying drawings, in which some, but not all, embodiments are shown. Indeed, the prosthetic heart valves, delivery devices, and methods disclosed may be embodied in many different forms and should not be construed as limited to the embodiments set forth herein; rather, these embodiments are provided so that this disclosure is thorough and complete and fully conveys the scope of the prosthetic heart valves, delivery devices, and methods to those skilled in the art. Like reference numbers refer to like elements throughout. The singular forms “a,” “an,” and “the” can refer to plural instances unless the context clearly dictates otherwise or unless explicitly stated.

As described in detail below, the embodiments of the present disclosure provide improved prosthetic heart valves, delivery devices, and methods for replacing diseased or defective native heart valves, such as mitral valves, aortic valves, pulmonary valves, or tricuspid valves, of a native human heart. In particular, some embodiments of the prosthetic heart valve may be configured for mitral valve replacement and may be implanted via open heart surgery or less-invasive approaches, such as a transapical approach, a transatrial approach, a transfemoral approach, a transseptal approach, a subclavian approach, a direct aortic puncture approach, or other vascular access approaches. Such embodiments of the prosthetic heart valve may accommodate the shape and structure of the native mitral valve and the surrounding anatomy without compromising the integrity or function of the surrounding anatomy. Such embodiments of the prosthetic heart valve also may securely anchor onto the native heart tissue to prevent or inhibit migration of the prosthetic heart valve from the implantation site. Further, such embodiments of the prosthetic heart valve may form a seal against the native heart tissue to prevent or inhibit paravalvular leakage.

Although the following description focuses primarily on use of the prosthetic heart valve for mitral valve replacement, it will be understood that some embodiments of the prosthetic heart valve may be configured for use in aortic, pulmonary, or tricuspid valve replacement. As will be appreciated by one of ordinary skill in the art, development of a prosthetic heart valve for replacement of the native mitral valve may present numerous technical and clinical challenges which must be taken in to account in order to provide a suitable prosthetic heart valve for mitral, aortic, pulmonary, or tricuspid valve replacement. For example, technical challenges and considerations include, but are not limited to, implanting the prosthetic heart valve at a narrow landing site on the native heart with limited imaging of the native heart anatomy and the prosthetic heart valve during implantation, navigating and accommodating the three-dimensional, dynamic native heart anatomy and complex sub-valvular features, accommodating the pressure gradient at the desired implantation site and the annular loads applied to the prosthetic heart valve by the native heart anatomy, providing adequate sealing against the native heart anatomy to prevent or inhibit paravalvular leakage, gaining access to the desired implantation site and guiding a relatively large prosthetic heart valve through the vasculature to the implantation site, avoiding undesirable thrombosis that may inhibit desired function of the prosthetic heart valve and/or surrounding features of the native heart, avoiding left ventricular outflow tract obstruction (LVOTO), and avoiding systolic anterior motion (SAM) of the mitral valve chordae tendineae. Clinical challenges and considerations include, but are not limited to, accommodating the particular complications of the sick population in need of valve replacement, identifying and addressing multiple and very different etiologies, such as ischemic, dilated cardiomyopathy, degenerative, and rheumatic etiologies, addressing an increased international normalized ratio (INR) because of thrombus potential including gastro-intestinal and other bleeds, and addressing atrial fibrillation.

According to one aspect, a prosthetic heart valve for replacing a diseased or defective native heart valve is provided. In one embodiment, the prosthetic heart valve may include an outer frame, an inner frame positioned at least partially within the outer frame, and an occluder member positioned at least partially within the inner frame. The prosthetic heart valve also may include an atrial flange extending from an atrial end of the outer frame, and a ventricular flange extending from a ventricular end of the outer frame, wherein at least a portion of the atrial flange extends radially outward beyond the ventricular flange.

Various aspects of the prosthetic heart valves, delivery devices, and methods described herein build upon those described in the following patent applications, which are incorporated by reference herein, in their entirety, for all purposes: U.S. application Ser. No. 11/888,009, filed Jul. 31, 2007; U.S. application Ser. No. 12/822,291, filed Jun. 24, 2010; U.S. application Ser. No. 13/339,236, filed Dec. 28, 2011; U.S. application Ser. No. 13/656,717, filed Oct. 21, 2012; U.S. application Ser. No. 13/772,203, filed Feb. 20, 2013; U.S. application Ser. No. 14/208,997, filed Mar. 13, 2014; U.S. application Ser. No. 14/278,594, filed May 15, 2014; PCT Application No. PCT/US2007/017061, filed Jul. 31, 2007; PCT Application No. PCT/US2011/067695, filed Dec. 29, 2011; PCT Application No. PCT/US2012/061292, filed Oct. 22, 2012; PCT Application No. PCT/US2013/027072, filed Feb. 21, 2013; and PCT Application No. PCT/US2014/038305, filed May 16, 2014. As will be appreciated by one of ordinary skill in the art, various features of the prosthetic heart valves, delivery devices, and methods described herein may be incorporated into the prosthetic heart valves, delivery devices, and methods described in the foregoing applications, and various features of the prosthetic heart valves, delivery devices, and methods described in the foregoing applications may be incorporated into the prosthetic heart valves, delivery devices, and methods described herein.

Referring now to the drawings, FIGS. 1A-1F illustrate an expandable prosthetic heart valve 100 (which also may be referred to as a “heart valve” or a “heart valve device”) according to one or more embodiments of the disclosure. In some embodiments, the prosthetic heart valve 100 may be configured for implantation at a diseased or defective native mitral valve of a human heart to replace the function of the native mitral valve. In other embodiments, the prosthetic heart valve 100 may be configured for implantation at a diseased or defective native aortic valve, pulmonary valve, or tricuspid valve of a human heart to replace the function of the native valve. As described below, the prosthetic heart valve 100 may accommodate the shape and structure of the native mitral valve and the surrounding anatomy without compromising the integrity or function of the surrounding anatomy, may securely anchor onto the native heart tissue to prevent or inhibit migration of the prosthetic heart valve 100 from the implantation site, and may form a seal against the native heart tissue to prevent or inhibit paravalvular leakage. Ultimately, the prosthetic heart valve 100 may restore desired function of the native heart by controlling blood flow in a manner similar to the native mitral valve being replaced.

The prosthetic heart valve 100 may be formed as a generally tubular structure having an elongated shape extending along a longitudinal axis of the heart valve 100. The prosthetic heart valve 100 may be implanted within the native mitral valve such that the longitudinal axis of the prosthetic heart valve 100 is generally aligned with the longitudinal axis of the native mitral valve. When positioned at the desired implantation site, an end portion of the heart valve 100 may be positioned within the left atrium of the heart, another end portion of the heart valve 100 may be positioned within the left ventricle of the heart, and an intermediate portion of the heart valve 100 may be positioned within the annulus of the native mitral valve. In this manner, the prosthetic heart valve 100 may have an atrial end 102 (which also may be referred to as a “proximal end” or a “first end”) and an ventricular end 104 (which also may be referred to as a “distal end” or a “second end”) positioned opposite the atrial end 102 along the longitudinal axis of the heart valve 100. As described below, the prosthetic heart valve 100 may be expandable, such that the heart valve 100 may be moved between a collapsed state for delivery of the heart valve 100 to the desired implantation site and an expanded state for anchoring the heart valve 100 to the heart at the implantation site. In particular, the prosthetic heart valve 100 may be configured for controlled expansion into one of a number of expanded states, such that the heart valve 100 may be expanded to an expanded state that corresponds to the size and shape of the anatomy of a particular patient. The prosthetic heart valve 100 also may be configured for controlled contraction from an expanded state toward or to the collapsed state, such that the heart valve 100 may be at least partially collapsed in order to reposition the heart valve 100 with respect to the heart anatomy, if necessary. In this manner, the prosthetic heart valve 100 may provide significant advantages over existing heart valves that are either self-expanding or are expanded by a balloon or other mechanism and do not provide a means for easily contracting or repositioning the heart valve.

The prosthetic heart valve 100 may include an outer frame 110 (which also may be referred to as a “radially outer frame”) and an inner frame 120 (which also may be referred to as a “radially inner frame”) positioned at least partially within the outer frame 110. The outer frame 110 may be a generally tubular structure having an elongated shape extending along the longitudinal axis of the heart valve 100. The outer frame 110 may be formed as a lattice or stent-like structure that radially expands and collapses as the prosthetic heart valve 100 is moved between the collapsed state and the expanded state. As shown, the lattice of the outer frame 110 may include a number of interconnected wire members 112 configured to deflect and/or articulate as the prosthetic heart valve 100 is moved between the collapsed state and the expanded state. The lattice of the outer frame 110 may be formed of a metal wire, although other materials and configurations of the lattice may be used. In some embodiments, the outer frame 110 may be formed of a shape memory alloy, such as nitinol, or a shape memory polymer, although other suitable metals, alloys, and polymers may be used. The lattice of the outer frame 110 may be configured such that controlled changes in the axial dimensions of the wire members 112 results in controlled changes to the orthogonal dimensions or diameter of the outer frame 110. Changes to the dimensions of the lattice of the outer frame 110 may be prescribed by mechanical interaction between the wire members 112 and other mechanical elements, such as screws or rods, which may define different positions for specific points in the lattice and, in doing so, may define an axial length of the lattice and thus its resulting diameter. For example, the outer frame 110 may include a number of actuator members 114 configured to facilitate movement of the prosthetic heart valve 100 between the collapsed state and the expanded state. In some embodiments, as shown, the actuator members 114 may include a threaded rod received within a threaded tube. The actuator members 114 may be attached to a number of the wire members 112, thereby forming a screw-jack mechanism to facilitate movement of the prosthetic heart valve 100 between the collapsed state and the expanded state. In other embodiments, the actuator members 114 may have other configurations for separately articulating the wire members 112 and selectively moving all or a portion of the prosthetic heart valve 100 between the collapsed state and the expanded state. In some embodiments, the actuator elements are rods that have multiple points that generate mechanical interference with a selective locking element at different states of expansion or contraction. The outer frame 110 may have a longitudinal axis which may be coaxial with or spaced apart from the longitudinal axis of the prosthetic heart valve 100. The outer frame 110 may have an atrial end 116 (which also may be referred to as a “proximal end” or a “first end”), and a ventricular end 118 (which also may be referred to as a “distal end” or a “second end”) positioned opposite the atrial end 116 along the longitudinal axis of the outer frame 110.

The inner frame 120 may be a generally tubular structure having an elongated shape extending along the longitudinal axis of the heart valve 100. The inner frame 120 also may be formed as a lattice or stent-like structure that radially expands and collapses as the prosthetic heart valve 100 is moved between the collapsed state and the expanded state. As shown, the lattice of the inner frame 120 may include a number of interconnected wire members 122 configured to deflect and/or articulate as the prosthetic heart valve 100 is moved between the collapsed state and the expanded state. The lattice of the inner frame 120 may be formed of a deformable metal wire, although other materials and configurations of the lattice may be used. In some embodiments, the inner frame 120 may be formed of a shape memory alloy, such as nitinol, or a shape memory polymer, although other suitable metals, alloys, and polymers may be used. although other suitable The inner frame 120 may have a longitudinal axis which may be coaxial with or spaced apart from the longitudinal axis of the prosthetic heart valve 100 and which may be coaxial with or spaced apart from the longitudinal axis of the outer frame 110. The inner frame 120 may have an atrial end 126 (which also may be referred to as a “proximal end” or a “first end”), and a ventricular end 128 (which also may be referred to as a “distal end” or a “second end”) positioned opposite the atrial end 126 along the longitudinal axis of the inner frame 120. As shown, the atrial end 126 of the inner frame 120 may be positioned within the lumen of the outer frame 110, and the ventricular end 128 of the inner frame 120 may be positioned outside of the lumen of the outer frame 110. In some embodiments, as shown, the ventricular end 128 of the inner frame 120 may be positioned at the ventricular end 104 of the prosthetic heart valve 100.

The outer frame 110 and the inner frame 120 may have a variety of cross-sectional shapes in a plane orthogonal to the longitudinal axes thereof. In various embodiments, the outer frame 110 may have a circular shape, an elliptical shape, a “D”-shape, a square shape, a rectangular shape, a polygonal shape, a curved shape, or a shape having one or more curved sections and one or more straight sections in the plane orthogonal to the longitudinal axis of the outer frame 110. In some embodiments, the cross-sectional shape of the outer frame 110 may be constant along the longitudinal direction. In other embodiments, the cross-sectional shape of the outer frame 110 may vary along the longitudinal direction. In some embodiments, the size of the cross-sectional shape of the outer frame 110 may be constant along the longitudinal direction. In other embodiments, the size of the cross-sectional shape of the outer frame 110 may vary along the longitudinal direction. In various embodiments, the inner frame 120 may have a circular shape, an elliptical shape, a “D”-shape, a square shape, a rectangular shape, a polygonal shape, a curved shape, or a shape having one or more curved sections and one or more straight sections in the plane orthogonal to the longitudinal axis of the inner frame 120. In some embodiments, the cross-sectional shape of the inner frame 120 may be constant along the longitudinal direction. In other embodiments, the cross-sectional shape of the inner frame 120 may vary along the longitudinal direction. In some embodiments, the size of the cross-sectional shape of the inner frame 120 may be constant along the longitudinal direction. In other embodiments, the size of the cross-sectional shape of the inner frame 120 may vary along the longitudinal direction. In some embodiments, the outer frame 110 may have a “D”-shape and the inner frame 120 may have a circular shape. In this manner, the outer frame 110 may be shaped to accommodate the generally “D”-shape of the native mitral valve, while the inner frame 120 may be shaped to accommodate an occluder member, such as a multi-leaflet valve, having a generally circular shape. Notably, use of the “D”-shaped outer frame 110 may reduce the possibility of left ventricular outflow tract obstruction. In other embodiments, the outer frame 110 may have a circular shape and the inner frame 120 may have a circular shape. In still other embodiments, the outer frame 110 and the inner frame 120 may have other shapes, which may be the same as or different from one another. In some embodiments, the outer frame 110 and the inner frame 120 may have the same longitudinal heights, although different longitudinal heights of the outer frame 110 and the inner frame 120 may be used in other embodiments.

As shown, the outer frame 110 and the inner frame 120 may be connected to one another by a trampoline 130 (which also may be referred to as an “intermediate frame” or an “intermediate support”) that extends radially between the outer frame 110 and the inner frame 120. In this manner, the trampoline 130 may maintain a relative position of the inner frame 120 with respect to the outer frame 110 and may guide the inner frame 120 during expansion and contraction of the prosthetic heart valve 100. In particular, the trampoline 130 may transfer forces from the outer frame 110 to the inner frame 120 as the outer frame 110 is expanded or collapsed, thereby causing the inner frame 120 to expand or collapse in a similar manner. As shown, the trampoline 130 may be formed as a lattice including a number of interconnected wire members 132 configured to deflect and/or articulate as the prosthetic heart valve 100 is moved between the collapsed state and the expanded state. The trampoline 130 may provide a contoured transition between the outer frame 110 and the inner frame 120, particularly when the outer frame 110 and the inner frame 120 have different cross-sectional shapes. In some embodiments, the trampoline 130 may be attached to the outer frame 110 and the inner frame 120 by mechanical fasteners, welding, soldering, bonding, chemical bonding or attachment, or other suitable means of attachment. In other embodiments, the outer frame 110, the inner frame 120, and the trampoline 130 may be formed from a single piece of material, which may be bent to form the respective shapes of the outer frame 110, the inner frame 120, and the trampoline 130.

As shown, the prosthetic heart valve 100 also may include a pair of flanges attached to the outer frame 110. In particular, the prosthetic heart valve 100 may include an atrial flange 140 (which also may be referred to as an “atrial skirt,” a “proximal flange,” a “proximal skirt,” or an “extended sealing surface”) attached to the atrial end 116 of the outer frame 110 and extending axially and/or radially outward therefrom. In some embodiments, the atrial flange 140 may be spaced apart from and positioned along the outer surface of the outer frame 110 distally from the atrial end 116 of the outer frame 110. During implantation of the prosthetic heart valve 100, the atrial flange 140 may be positioned within the left atrium of the heart and in apposition against a tissue surface therein above the mitral valve annulus. The atrial flange 140 may be flexible such that the atrial flange 140 may be collapsed and expanded along with the outer frame 110 to facilitate positioning and anchoring of the outer frame 110 at the implantation site. As shown, the atrial flange 140 may include a number of petals 142 positioned in a circumferential array along the circumference of the outer frame 110. The petals 142 may be formed of a metal or polymer wire, although other materials and configurations of the petals 142 may be used. In some embodiments, the petals 142 may be formed of wire mesh or stent lattice.

The prosthetic heart valve 100 also may include a ventricular flange 150 (which also may be referred to as a “ventricular skirt,” a “distal flange,” a “distal skirt,” or an “extended sealing surface”) attached to the ventricular end 118 of the outer frame 110 and extending axially and radially outward therefrom. In some embodiments, the ventricular flange 150 may be spaced apart from and positioned along the outer surface of the outer frame 110 proximally from the ventricular end 118 of the outer frame 110. During implantation of the prosthetic heart valve 100, the ventricular flange 150 may be positioned within the left ventricle of the heart and in apposition against a tissue surface therein below the mitral valve annulus. The ventricular flange 150 may be flexible such that the ventricular flange 150 may be collapsed and expanded along with the outer frame 110 to facilitate positioning and anchoring of the outer frame 110 at the implantation site. As shown, the ventricular flange 150 may include a number of petals 152 positioned in a circumferential array along the circumference of the outer frame 110. The petals 152 may be formed of a metal or polymer wire, although other materials and configurations of the petals 152 may be used. In some embodiments, the petals 152 may be formed of wire mesh or stent lattice.

Notably, the atrial flange 140 and the ventricular flange 150 may facilitate mechanical interference based anchoring of the prosthetic heart valve 100 onto the heart as well as pressure-driven sealing between the heart valve 100 and the mating heart tissue. Such anchoring and sealing benefits may be particularly advantageous in mitral valve replacement because the presence of the left ventricular outflow tract, the more compliant tissue, the shorter annuli, and the increased area of dilated annuli do not allow for reliance only on radial force for sealing and anchoring, as in aortic valve replacement. In some embodiments, the ventricular flange 150 may be larger than the atrial flange 140, such that the ventricular flange 150 has a larger cross-sectional area than the atrial flange 140 in the plane orthogonal to the longitudinal axis of the. In some embodiments, at least a portion of the ventricular flange 150 may extend radially outward beyond the atrial flange 140. In other embodiments, the ventricular flange 150 may extend radially outward beyond the atrial flange 140 along the entire circumference of the flanges 140, 150. In some embodiments, all of the petals 142 of the atrial flange 140 may have the same size, with the same axial length and the same radial length. In other embodiments, the petals 142 of the atrial flange 140 may vary in their axial length and/or their radial length along the circumference of the atrial flange 140. In some embodiments, one or more of the petals 142 configured to be positioned at or near the trigones of the mitral valve may be stiffer and/or longer that a remainder of the petals 142. In this manner, such embodiments may provide enhanced anchoring about the trigones of the mitral valve. In some embodiments, all of the petals 152 of the ventricular flange 150 may have the same size, with the same axial length and the same radial length. In other embodiments, the petals 152 of the ventricular flange 150 may vary in their axial length and/or their radial length along the circumference of the ventricular flange 150. In some embodiments, one or more of the petals 152 configured to be positioned at or near the trigones of the mitral valve may be stiffer and/or longer that a remainder of the petals 152. In this manner, such embodiments may provide enhanced anchoring about the trigones of the mitral valve.

As shown, the prosthetic heart valve 100 may include a biocompatible covering 160 (which also may be referred to as a “membrane”) positioned over portions of the outer frame 110, the inner frame 120, the trampoline 130, the atrial flange 140, and/or the ventricular flange 150. The outer frame 110, the inner frame 120, the trampoline 130, the atrial flange 140, and/or the ventricular flange 150 each may be partially or entirely covered by the covering 160, according to various embodiments. The covering 160 may be formed as a single component positioned over the respective portions of the heart valve 100 or as multiple components positioned over the respective portions of the heart valve 100. In some embodiments, the covering 160 extends over the outer surfaces and/or the inner surfaces of the outer frame 110, the inner frame 120, the trampoline 130, the atrial flange 140, and/or the ventricular flange 150. In some embodiments, the covering 160 is formed of a biocompatible cloth or textile material, although other suitable materials may be used for the covering 160. When the prosthetic heart valve 100 is implanted, the covering 160 may promote hemostasis at the implantation site, preventing or inhibiting blood flow around the heart valve 100. The covering 160 also may promote tissue ingrowth or overgrowth to facilitate anchoring of the prosthetic heart valve 100 to the heart tissue.

The prosthetic heart valve 100 further may include an occluder member 170 (which also may be referred to simply as an “occluder”) attached to the inner frame 120 and positioned at least partially within the lumen thereof. The occluder member 170 may be configured to control blood blow through the prosthetic heart valve 100 in a manner similar to the native heart valve being replaced. In some embodiments, as shown, the occluder member 170 may be a multi-leaflet valve including a number of leaflets 172 arranged to form a one-way valve to control blood flow therebetween. The leaflets 172 may be formed of a metal, a polymer, a ceramic, a composite material, or a bioprosthetic material. For example, the leaflets 172 may be bioprosthetic leaflets of treated animal tissue, such as porcine, bovine, or equine tissue. In other embodiments, the occluder member 170 may include one or more spheres, one or more discs, one or more rotating plates, or other types of members configured to control blood flow. Any such embodiments may be configured as a one-directional occluder member, allowing blood flow therethrough in one direction and preventing blood flow in an opposite direction.

In some embodiments, the prosthetic heart valve 100 also may include one or more anchors attached to the outer frame 110 and extending radially outward therefrom. During implantation of the prosthetic heart valve 100, the anchors may be configured to pierce or create a mechanical interference with the surrounding heart tissue, such as the native mitral valve annulus. In this manner, the anchors may further secure the position of the prosthetic heart valve 100 at the implantation site. In some embodiments, the anchors may be fixed relative to the outer frame 110 and may engage the surrounding heart tissue as the prosthetic heart valve 100 is expanded within the native mitral valve. In other embodiments, the anchors may be deployed from a retracted state for positioning of the prosthetic heart valve 100 to a deployed state for engaging the surrounding heart tissue. In some embodiments, the anchors may be formed as prongs or hooks, although other configurations of the anchors may be used.

The prosthetic heart valve 100 may be delivered to the desired implantation site and anchored to the native heart via a delivery device 180. As shown, the delivery device 180 may include a shaft 182 with a guide tip 184 attached to a distal end of the shaft 182. During use of the delivery device 180, the guide tip 184 and a distal portion of the shaft 182 may extend through the prosthetic heart valve 100, as shown, to guide the prosthetic heart valve 100 through the vasculature to the implantation site. The delivery device 180 also may include a sheath positioned over the shaft 182 and configured to retain the prosthetic heart valve 100 in the collapsed state therein until the distal end portion of the delivery device 180 reaches the implantation site. The sheath then may be retracted to expose the prosthetic heart valve 100. The delivery device 180 also may include a number of control wires 186 configured to attach to the actuator members 114 of the outer frame 110. In some embodiments, the control wires 186 may be threaded and configured to threadably attach to the actuator members 114, although other means of attachment may be used. After the prosthetic heart valve 100 is exposed and positioned within the native mitral valve, the control wires 186 may be manipulated to actuate the actuator members 114, thereby causing the outer frame 110 to controllably expand from the collapsed state. As described above, expansion of the outer frame 110 also may cause the inner frame 120 to expand. The prosthetic heart valve 100 may be expanded in this manner within the native mitral valve until the outer surface of the outer frame 110 sufficiently engages the native mitral valve annulus to maintain a relative position of the prosthetic heart valve 100 with respect to the native mitral valve. Upon such expansion, the anchors, if present, may engage the mitral valve annulus or other heart tissue. Meanwhile, the ventricular flange 150 may expand within the left ventricle of the heart and engage the tissue surface below the mitral valve annulus. Once the desired positioning of the prosthetic heart valve 100 within the native mitral valve is obtained, the control wires 186 may be disengaged from the actuator members 114. Upon disengaging the control wires 186, the atrial flange 140 may expand within the left atrium and engage the tissue surface above the mitral valve annulus. Ultimately, the engagement between the outer frame 110 and the mitral valve annulus, the engagement between the ventricular flange 150 and the mating tissue surface, and the engagement between the atrial flange 140 and the mating tissue surface may securely anchor the prosthetic heart valve 100 within the native mitral valve. In embodiments that include the anchors, the engagement between the anchors and the mating tissue may further anchor the prosthetic heart valve 100. Meanwhile, the engagement between the covering 160 and the mating tissue surfaces, the engagement between the ventricular flange 150 and the mating tissue surface, and the engagement between the atrial flange 140 and the mating tissue surface may provide one or more seals that prevent or inhibit blood flow around the prosthetic heart valve 100 and also may promote tissue ingrowth or overgrowth to further seal and anchor the prosthetic heart valve 100. The prosthetic heart valve 100 described herein may be configured for anchoring onto a mitral valve annulus having a commissural diameter in the range of between 2 cm and 7 cm, which may cover a majority of patients in need of heart valve replacement.

FIGS. 2A-2J illustrate an expandable prosthetic heart valve 200 (which also may be referred to as a “heart valve” or a “heart valve device”) according to one or more embodiments of the disclosure. In some embodiments, the prosthetic heart valve 200 may be configured for implantation at a diseased or defective native mitral valve of a human heart to replace the function of the native mitral valve. In other embodiments, the prosthetic heart valve 200 may be configured for implantation at a diseased or defective native aortic valve, pulmonary valve, or tricuspid valve of a human heart to replace the function of the native valve. As described below, the prosthetic heart valve 200 may accommodate the shape and structure of the native mitral valve and the surrounding anatomy without compromising the integrity or function of the surrounding anatomy, may securely anchor onto the native heart tissue to prevent or inhibit migration of the prosthetic heart valve 200 from the implantation site, and may form a seal against the native heart tissue to prevent or inhibit paravalvular leakage. Ultimately, the prosthetic heart valve 200 may restore desired function of the native heart by controlling blood flow in a manner similar to the native mitral valve being replaced.

The prosthetic heart valve 200 may be formed as a generally tubular structure having an elongated shape extending along a longitudinal axis of the heart valve 200. The prosthetic heart valve 200 may be implanted within the native mitral valve such that the longitudinal axis of the prosthetic heart valve 200 is generally aligned with the longitudinal axis of the native mitral valve. When positioned at the desired implantation site, an end portion of the heart valve 200 may be positioned within the left atrium of the heart, another end portion of the heart valve 200 may be positioned within the left ventricle of the heart, and an intermediate portion of the heart valve 200 may be positioned within the annulus of the native mitral valve. In this manner, the prosthetic heart valve 200 may have an atrial end 202 (which also may be referred to as a “proximal end” or a “first end”) and an ventricular end 204 (which also may be referred to as a “distal end” or a “second end”) positioned opposite the atrial end 202 along the longitudinal axis of the heart valve 200. As described below, the prosthetic heart valve 200 may be expandable, such that the heart valve 200 may be moved between a collapsed state for delivery of the heart valve 200 to the desired implantation site and an expanded state for anchoring the heart valve 200 to the heart at the implantation site. In particular, the prosthetic heart valve 200 may be configured for controlled expansion into one of a number of expanded states, such that the heart valve 200 may be expanded to an expanded state that corresponds to the size and shape of the anatomy of a particular patient. The prosthetic heart valve 200 also may be configured for controlled contraction from an expanded state toward or to the collapsed state, such that the heart valve 200 may be at least partially collapsed in order to reposition the heart valve 200 with respect to the heart anatomy, if necessary. In this manner, the prosthetic heart valve 200 may provide significant advantages over existing heart valves that are either self-expanding or are expanded by a balloon or other mechanism and do not provide a means for easily contracting or repositioning the heart valve.

The prosthetic heart valve 200 may include an outer frame 210 (which also may be referred to as a “radially outer frame”) and an inner frame 220 (which also may be referred to as a “radially inner frame”) positioned at least partially within the outer frame 210. The outer frame 210 may be a generally tubular structure having an elongated shape extending along the longitudinal axis of the heart valve 200. The outer frame 210 may be formed as a lattice or stent-like structure that radially expands and collapses as the prosthetic heart valve 200 is moved between the collapsed state and the expanded state. As shown, the lattice of the outer frame 210 may include a number of interconnected wire members 212 configured to deflect and/or articulate as the prosthetic heart valve 200 is moved between the collapsed state and the expanded state. The lattice of the outer frame 210 may be formed of a metal wire, although other materials and configurations of the lattice may be used. In some embodiments, the outer frame 210 may be formed of a shape memory alloy, such as nitinol, or a shape memory polymer, although other suitable metals, alloys, and polymers may be used. The lattice of the outer frame 210 may be configured such that controlled changes in the axial dimensions of the wire members 212 results in controlled changes to the orthogonal dimensions or diameter of the outer frame 210. Changes to the dimensions of the lattice of the outer frame 210 may be prescribed by mechanical interaction between the wire members 212 and other mechanical elements, such as screws or rods, which may define different positions for specific points in the lattice and, in doing so, may define an axial length of the lattice and thus its resulting diameter. For example, the outer frame 210 may include a number of actuator members 214 configured to facilitate movement of the prosthetic heart valve 200 between the collapsed state and the expanded state. In some embodiments, as shown, the actuator members 214 may include a threaded rod received within a threaded tube. The actuator members 214 may be attached to a number of the wire members 212, thereby forming a screw-jack mechanism to facilitate movement of the prosthetic heart valve 200 between the collapsed state and the expanded state. In other embodiments, the actuator members 214 may have other configurations for articulating the wire members 212 and moving the prosthetic heart valve 200 between the collapsed state and the expanded state. The outer frame 210 may have a longitudinal axis which may be coaxial with or spaced apart from the longitudinal axis of the prosthetic heart valve 200. The outer frame 210 may have an atrial end 216 (which also may be referred to as a “proximal end” or a “first end”), and a ventricular end 218 (which also may be referred to as a “distal end” or a “second end”) positioned opposite the atrial end 216 along the longitudinal axis of the outer frame 210.

The inner frame 220 may be a generally tubular structure having an elongated shape extending along the longitudinal axis of the heart valve 200. The inner frame 220 also may be formed as a lattice or stent-like structure that radially expands and collapses as the prosthetic heart valve 200 is moved between the collapsed state and the expanded state. As shown, the lattice of the inner frame 220 may include a number of interconnected wire members 222 configured to deflect and/or articulate as the prosthetic heart valve 200 is moved between the collapsed state and the expanded state. The lattice of the inner frame 220 may be formed of a deformable metal wire, although other materials and configurations of the lattice may be used. In some embodiments, the inner frame 220 may be formed of a shape memory alloy, such as nitinol, or a shape memory polymer, although other suitable metals, alloys, and polymers may be used. although other suitable The inner frame 220 may have a longitudinal axis which may be coaxial with or spaced apart from the longitudinal axis of the prosthetic heart valve 200 and which may be coaxial with or spaced apart from the longitudinal axis of the outer frame 210. The inner frame 220 may have an atrial end 226 (which also may be referred to as a “proximal end” or a “first end”), and a ventricular end 228 (which also may be referred to as a “distal end” or a “second end”) positioned opposite the atrial end 226 along the longitudinal axis of the inner frame 220. As shown, the atrial end 226 of the inner frame 220 may be positioned within the lumen of the outer frame 210, and the ventricular end 228 of the inner frame 220 may be positioned outside of the lumen of the outer frame 210. In some embodiments, as shown, the ventricular end 228 of the inner frame 220 may be positioned at the ventricular end 204 of the prosthetic heart valve 200.

The outer frame 210 and the inner frame 220 may have a variety of cross-sectional shapes in a plane orthogonal to the longitudinal axes thereof. In various embodiments, the outer frame 210 may have a circular shape, an elliptical shape, a “D”-shape, a square shape, a rectangular shape, a polygonal shape, a curved shape, or a shape having one or more curved sections and one or more straight sections in the plane orthogonal to the longitudinal axis of the outer frame 210. In some embodiments, the cross-sectional shape of the outer frame 210 may be constant along the longitudinal direction. In other embodiments, the cross-sectional shape of the outer frame 210 may vary along the longitudinal direction. In some embodiments, the size of the cross-sectional shape of the outer frame 210 may be constant along the longitudinal direction. In other embodiments, the size of the cross-sectional shape of the outer frame 210 may vary along the longitudinal direction. In various embodiments, the inner frame 220 may have a circular shape, an elliptical shape, a “D”-shape, a square shape, a rectangular shape, a polygonal shape, a curved shape, or a shape having one or more curved sections and one or more straight sections in the plane orthogonal to the longitudinal axis of the inner frame 220. In some embodiments, the cross-sectional shape of the inner frame 220 may be constant along the longitudinal direction. In other embodiments, the cross-sectional shape of the inner frame 220 may vary along the longitudinal direction. In some embodiments, the size of the cross-sectional shape of the inner frame 220 may be constant along the longitudinal direction. In other embodiments, the size of the cross-sectional shape of the inner frame 220 may vary along the longitudinal direction. In some embodiments, the outer frame 210 may have a “D”-shape and the inner frame 220 may have a circular shape. In this manner, the outer frame 210 may be shaped to accommodate the generally “D”-shape of the native mitral valve, while the inner frame 220 may be shaped to accommodate an occluder member, such as a multi-leaflet valve, having a generally circular shape. Notably, use of the “D”-shaped outer frame 210 may reduce the possibility of left ventricular outflow tract obstruction. In other embodiments, the outer frame 210 may have a circular shape and the inner frame 220 may have a circular shape. In still other embodiments, the outer frame 210 and the inner frame 220 may have other shapes, which may be the same as or different from one another. In some embodiments, the outer frame 210 and the inner frame 220 may have the same longitudinal heights, although different longitudinal heights of the outer frame 210 and the inner frame 220 may be used in other embodiments.

As shown, the outer frame 210 and the inner frame 220 may be connected to one another by a trampoline 230 (which also may be referred to as an “intermediate frame” or an “intermediate support”) that extends radially between the outer frame 210 and the inner frame 220. In this manner, the trampoline 230 may maintain a relative position of the inner frame 220 with respect to the outer frame 210 and may guide the inner frame 220 during expansion and contraction of the prosthetic heart valve 200. In particular, the trampoline 230 may transfer forces from the outer frame 210 to the inner frame 220 as the outer frame 210 is expanded or collapsed, thereby causing the inner frame 220 to expand or collapse in a similar manner. As shown, the trampoline 230 may be formed as a lattice including a number of interconnected wire members 232 configured to deflect and/or articulate as the prosthetic heart valve 200 is moved between the collapsed state and the expanded state. The trampoline 230 may provide a contoured transition between the outer frame 210 and the inner frame 220, particularly when the outer frame 210 and the inner frame 220 have different cross-sectional shapes. In some embodiments, the trampoline 230 may be attached to the outer frame 210 and the inner frame 220 by mechanical fasteners, welding, soldering, bonding, chemical bonding or attachment, or other suitable means of attachment. In other embodiments, the outer frame 210, the inner frame 220, and the trampoline 230 may be formed from a single piece of material, which may be bent to form the respective shapes of the outer frame 210, the inner frame 220, and the trampoline 230.

As shown, the prosthetic heart valve 200 also may include a pair of flanges attached to the outer frame 210. In particular, the prosthetic heart valve 200 may include an atrial flange 240 (which also may be referred to as an “atrial skirt,” a “proximal flange,” a “proximal skirt,” or an “extended sealing surface”) attached to the atrial end 216 of the outer frame 210 and extending axially and/or radially outward therefrom. In some embodiments, the atrial flange 240 may be spaced apart from and positioned along the outer surface of the outer frame 210 distally from the atrial end 216 of the outer frame 210. During implantation of the prosthetic heart valve 200, the atrial flange 240 may be positioned within the left atrium of the heart and in apposition against a tissue surface therein above the mitral valve annulus. The atrial flange 240 may be flexible such that the atrial flange 240 may be collapsed and expanded along with the outer frame 210 to facilitate positioning and anchoring of the outer frame 210 at the implantation site. As shown, the atrial flange 240 may include a number of petals 242 positioned in a circumferential array along the circumference of the outer frame 210. The petals 242 may be formed of a metal or polymer wire, although other materials and configurations of the petals 242 may be used. In some embodiments, the petals 242 may be formed of wire mesh or stent lattice.

The prosthetic heart valve 200 also may include a ventricular flange 250 (which also may be referred to as a “ventricular skirt,” a “distal flange,” a “distal skirt,” or an “extended sealing surface”) attached to the ventricular end 218 of the outer frame 210 and extending axially and radially outward therefrom. In some embodiments, the ventricular flange 250 may be spaced apart from and positioned along the outer surface of the outer frame 210 proximally from the ventricular end 218 of the outer frame 210. During implantation of the prosthetic heart valve 200, the ventricular flange 250 may be positioned within the left ventricle of the heart and in apposition against a tissue surface therein below the mitral valve annulus. The ventricular flange 250 may be flexible such that the ventricular flange 250 may be collapsed and expanded along with the outer frame 210 to facilitate positioning and anchoring of the outer frame 210 at the implantation site. As shown, the ventricular flange 250 may include a number of petals 252 positioned in a circumferential array along the circumference of the outer frame 210. The petals 252 may be formed of a metal or polymer wire, although other materials and configurations of the petals 252 may be used. In some embodiments, the petals 252 may be formed of wire mesh or stent lattice.

Notably, the atrial flange 240 and the ventricular flange 250 may facilitate mechanical interference based anchoring of the prosthetic heart valve 200 onto the heart as well as pressure-driven sealing between the heart valve 200 and the mating heart tissue. Such anchoring and sealing benefits may be particularly advantageous in mitral valve replacement because the presence of the left ventricular outflow tract, the more compliant tissue, the shorter annuli, and the increased area of dilated annuli do not allow for reliance only on radial force for sealing and anchoring, as in aortic valve replacement. In some embodiments, the ventricular flange 250 may be larger than the atrial flange 240, such that the ventricular flange 250 has a larger cross-sectional area than the atrial flange 240 in the plane orthogonal to the longitudinal axis of the. In some embodiments, at least a portion of the ventricular flange 250 may extend radially outward beyond the atrial flange 240. In other embodiments, the ventricular flange 250 may extend radially outward beyond the atrial flange 240 along the entire circumference of the flanges 240, 250. In some embodiments, all of the petals 242 of the atrial flange 240 may have the same size, with the same axial length and the same radial length. In other embodiments, the petals 242 of the atrial flange 240 may vary in their axial length and/or their radial length along the circumference of the atrial flange 240. In some embodiments, one or more of the petals 242 configured to be positioned at or near the trigones of the mitral valve may be stiffer and/or longer that a remainder of the petals 242. In this manner, such embodiments may provide enhanced anchoring about the trigones of the mitral valve. In some embodiments, the petals on the anterior section of the valve which lie between the trigones may be shorter or have another preferential shapes, so as to interfere less with the aortic root. In some embodiments, all of the petals 252 of the ventricular flange 250 may have the same size, with the same axial length and the same radial length. In other embodiments, the petals 252 of the ventricular flange 250 may vary in their axial length and/or their radial length along the circumference of the ventricular flange 250. In some embodiments, one or more of the petals 252 configured to be positioned at or near the trigones of the mitral valve may be stiffer and/or longer that a remainder of the petals 252. In this manner, such embodiments may provide enhanced anchoring about the trigones of the mitral valve. In some embodiments, the petals or any other anchor in the commissural areas in the atrial and/or ventricular sides of the valve, may be configured by location or shape to pass partially or fully between the leaflets, at the commissural edge in order to interfere minimally with leaflet motion.

As shown, the prosthetic heart valve 200 may include a biocompatible covering 260 (which also may be referred to as a “membrane”) positioned over portions of the outer frame 210, the inner frame 220, the trampoline 230, the atrial flange 240, and/or the ventricular flange 250. The outer frame 210, the inner frame 220, the trampoline 230, the atrial flange 240, and/or the ventricular flange 250 each may be partially or entirely covered by the covering 260, according to various embodiments. The covering 260 may be formed as a single component positioned over the respective portions of the heart valve 200 or as multiple components positioned over the respective portions of the heart valve 200. In some embodiments, the covering 260 extends over the outer surfaces and/or the inner surfaces of the outer frame 210, the inner frame 220, the trampoline 230, the atrial flange 240, and/or the ventricular flange 250. In some embodiments, the covering 260 is formed of a biocompatible cloth or textile material, although other suitable materials may be used for the covering 260. When the prosthetic heart valve 200 is implanted, the covering 260 may promote hemostasis at the implantation site, preventing or inhibiting blood flow around the heart valve 200. The covering 260 also may promote tissue ingrowth or overgrowth to facilitate anchoring of the prosthetic heart valve 200 to the heart tissue.

The prosthetic heart valve 200 further may include an occluder member 270 (which also may be referred to simply as an “occluder”) attached to the inner frame 220 and positioned at least partially within the lumen thereof. The occluder member 270 may be configured to control blood blow through the prosthetic heart valve 200 in a manner similar to the native heart valve being replaced. In some embodiments, as shown, the occluder member 270 may be a multi-leaflet valve including a number of leaflets 272 arranged to form a one-way valve to control blood flow therebetween. The leaflets 272 may be formed of a metal, a polymer, a ceramic, a composite material, or a bioprosthetic material. For example, the leaflets 272 may be bioprosthetic leaflets of treated animal tissue, such as porcine, bovine, or equine tissue. In other embodiments, the occluder member 270 may include one or more spheres, one or more discs, one or more rotating plates, or other types of members configured to control blood flow. Any such embodiments may be configured as a one-directional occluder member, allowing blood flow therethrough in one direction and preventing blood flow in an opposite direction.

In some embodiments, the prosthetic heart valve 200 also may include one or more anchors 274 attached to the outer frame 210 and extending radially outward therefrom. During implantation of the prosthetic heart valve 200, the anchors 274 may be configured to pierce or create a mechanical interference with the surrounding heart tissue, such as the native mitral valve annulus. In this manner, the anchors 274 may further secure the position of the prosthetic heart valve 200 at the implantation site. In some embodiments, the anchors 274 may be fixed relative to the outer frame 210 and may engage the surrounding heart tissue as the prosthetic heart valve 200 is expanded within the native mitral valve. In other embodiments, as shown, the anchors 274 may be deployed from a retracted state for positioning of the prosthetic heart valve 200 to a deployed state for engaging the surrounding heart tissue. In some embodiments, the anchors 274 may be formed as prongs or hooks, although other configurations of the anchors may be used.

The prosthetic heart valve 200 may be delivered to the desired implantation site and anchored to the native heart via a delivery device 280. As shown, the delivery device 280 may include a shaft 282 with a guide tip 284 attached to a distal end of the shaft 282. During use of the delivery device 280, the guide tip 284 and a distal portion of the shaft 282 may extend through the prosthetic heart valve 200, as shown, to guide the prosthetic heart valve 200 through the vasculature to the implantation site. The delivery device 280 also may include a sheath positioned over the shaft 282 and configured to retain the prosthetic heart valve 200 in the collapsed state therein until the distal end portion of the delivery device 280 reaches the implantation site. The sheath then may be retracted to expose the prosthetic heart valve 200. The delivery device 280 also may include a number of control wires 286 configured to attach to the actuator members 214 of the outer frame 210. In some embodiments, the control wires 286 may be threaded and configured to threadably attach to the actuator members 214, although other means of attachment may be used. After the prosthetic heart valve 200 is exposed and positioned within the native mitral valve, the control wires 286 may be manipulated to actuate the actuator members 214, thereby causing the outer frame 210 to controllably expand from the collapsed state. As described above, expansion of the outer frame 210 also may cause the inner frame 220 to expand. The prosthetic heart valve 200 may be expanded in this manner within the native mitral valve until the outer surface of the outer frame 210 sufficiently engages the native mitral valve annulus to maintain a relative position of the prosthetic heart valve 200 with respect to the native mitral valve. Upon such expansion, the anchors 274, if present, may engage the mitral valve annulus or other heart tissue. Meanwhile, the ventricular flange 250 may expand within the left ventricle of the heart and engage the tissue surface below the mitral valve annulus. Once the desired positioning of the prosthetic heart valve 200 within the native mitral valve is obtained, the control wires 286 may be disengaged from the actuator members 214. Upon disengaging the control wires 286, the atrial flange 240 may expand within the left atrium and engage the tissue surface above the mitral valve annulus. Ultimately, the engagement between the outer frame 210 and the mitral valve annulus, the engagement between the ventricular flange 250 and the mating tissue surface, and the engagement between the atrial flange 240 and the mating tissue surface may securely anchor the prosthetic heart valve 200 within the native mitral valve. In embodiments that include the anchors 274, the engagement between the anchors 274 and the mating tissue may further anchor the prosthetic heart valve 200. Meanwhile, the engagement between the covering 260 and the mating tissue surfaces, the engagement between the ventricular flange 250 and the mating tissue surface, and the engagement between the atrial flange 240 and the mating tissue surface may provide one or more seals that prevent or inhibit blood flow around the prosthetic heart valve 200 and also may promote tissue ingrowth or overgrowth to further seal and anchor the prosthetic heart valve 200. The prosthetic heart valve 200 described herein may be configured for anchoring onto a mitral valve annulus having a commissural diameter in the range of between 2 cm and 7 cm, which may cover a majority of patients in need of heart valve replacement.

FIGS. 3A-3F show an exemplary method for controllably delivering an expandable mitral valve with a double frame of an embodiment of the present invention. FIG. 3A shows the approach to the mitral valve. FIG. 3B shows unsheathing of the ventricular skirt. FIG. 3C shows controlled expansion of the frame, allowing repositioning or re-sheathing by contracting the frame. FIG. 3D shows the atrial petals open for positioning and hemodynamic function verification. Repositioning can be achieved by contracting the frame. Re-sheathing can be achieved by contracting the frame and bringing in the petals with control wires. FIG. 3E shows two views of releasing the control wires in the final position. FIG. 3F shows two views of removing the guide wire and final verification of the valve position and function.

In some embodiments, the steps described in FIGS. 3A-3F may be used to deploy the valve, in the proposed sequence or in another sequence of steps. The delivery may be transatrial, trans-apical, venous, trans-septal or any other vascular or non-vascular route. In one embodiment the system may be electromechanical and computer controlled in order to facilitate the steps for delivery, deployment, anchoring, re-sheathing and release.

FIGS. 3G-3L show a method for controlled re-sheathing of an expandable mitral valve with petals of an embodiment of the present invention. FIG. 3G illustrates how a single button operation minimizes complexity in re-sheathing atrial petals after deployment. FIG. 3H shows how control wires pass outside or within slots in atrial petals to enable inward deflection. FIG. 3I shows coordinated contraction of stent and forward motion of sheath allow for petals to be retracted into the frame. FIG. 3J shows that at minimum driven size, the sheath moves forward and can pass over a funneled ventricular skirt. FIG. 3K shows a super-elastic nitinol tip that forms a funnel to reduce friction, and that the structure from a multi-lumen tube allows the use of wires to pull petals inward without damaging the tip. FIG. 3L shows the nitinol tip recoils into a straight configuration after passing over the implant.

Therefore, in some embodiments, the valve may be fully repositioned or re-sheathed as shown in the method illustrated in FIGS. 3G-3L. In order to re-sheath the heart valve device, in some embodiments the control wires of the delivery device may be used to deflect the petals or other anchoring members in order to re-sheath them. In one embodiment, the control wires will pass on the outside of the ventricular or atrial petals, so that so they can be used to deform inward those petals, or other anchoring elements, so that the sheath can move over them. In one embodiment, guide elements or channels on the petals or control wires may be used so as to allow mechanical deflection without the wires slipping on the surface of the petals. In some embodiments, those petals may be covered by a cloth or other surface coating which may interfere with forward sheath motion when moving forward over the petals or other anchoring elements. In such cases, the control with other elongated elements from the delivery device may be used to bend in preferential directions the cloth or other surface in order to minimize interference with the motion of the sheath. In other embodiments, other types of mechanical elements, including but not limited to wires, rods and hooks, may extend from the delivery device and allow for inward deflection of the atrial and/or ventricular petals and/or other anchoring elements in order to minimize interference with sheath in the re-sheathing process.

In some embodiments, the guide tip can have a shape or slit on its surface to interfere with the tip of the sheath. In some embodiments, the tip of the sheath has a trumpet or expanded shape, which can be collapsed and sustained in the collapsed state by mechanical interference with the guide tip. As the sheath is retracted during deployment and interference is lost with the guide tip, the distal end of the sheath expands, which allows for easier re-sheathing of the implant. An expandable sheath tip will also allow reduction of the re-sheathing force and decrease interference when the sheath moves over the petals or anchoring elements of the implant.

In some embodiments, the actuator elements can be independently controlled in order to generate desired shape changes in the inner and/or outer frame. In some embodiments, actuators on the anterior section of the external frame can be controlled independently of actuators in the posterior section of the outer frame. In this embodiment, during expansion the user may preferentially expand the anterior section of the frame to achieve the correct inter-trigonal length and expand the posterior section of the frame in order to have an improved fit and seal of the elements against the tissue.

Many modifications of the embodiments of the present disclosure will come to mind to one skilled in the art to which the disclosure pertains upon having the benefit of the teachings presented herein through the foregoing descriptions and the associated drawings. Therefore, it is to be understood that the present invention is not to be limited to the specific embodiments disclosed and that modifications and other embodiments are intended to be included within the scope of the appended claims. Although specific terms are employed herein, they are used in a generic and descriptive sense only and not for purposes of limitation.

Claims

1. A prosthetic heart valve comprising: a first tubular frame comprising a plurality of interconnected wire members, an inflow end portion, and an outflow end portion, wherein the first tubular frame is movable between a radially collapsed state and a radially expanded state, and wherein the plurality of interconnected wire members deflect relative to each other as the first tubular frame moves between the radially collapsed state and the radially expanded state;a second tubular frame disposed at least partially within and coupled to the first tubular frame;a valve member disposed within and coupled to the second tubular frame, wherein the valve member comprises a plurality of leaflets arranged to form a one-way valve to control blood flow therebetween;one or more actuator members coupled to the plurality of interconnected wire members of the first tubular frame, wherein the actuator members are configured to facilitate movement of the first tubular frame between the radially collapsed state and the radially expanded state; anda flange coupled to and extending radially outwardly from the first tubular frame, wherein the flange comprises a plurality of deflectable petals configured to move between a first state and a second state, wherein the plurality of deflectable petals comprises a first petal having a first length and a second petal having a second length, and wherein the first length is different than the second length.
2. The prosthetic heart valve of claim 1, wherein the flange is coupled to the inflow end portion of the first tubular frame.
3. The prosthetic heart valve of claim 2, wherein the flange is a first flange, wherein the prosthetic heart valve further comprises a second flange coupled to the outflow end portion of the first tubular frame.
4. The prosthetic heart valve of claim 3, wherein at least a portion of the first flange extends radially outwardly beyond the second flange.
5. The prosthetic heart valve of claim 3, wherein the plurality of deflectable petals is a first plurality of deflectable petals, wherein the second flange comprises a second plurality of deflectable petals configured to move between a folded state and an unfolded state, wherein the second plurality of deflectable petals comprises a third petal having a third length and a fourth petal having a fourth length, and wherein the third length is different than the fourth length.
6. The prosthetic heart valve of claim 5, wherein at least a portion of the first flange extends radially outwardly beyond the second flange.
7. The prosthetic heart valve of claim 1, wherein the flange is coupled to the outflow end portion of the first tubular frame.
8. The prosthetic heart valve of claim 1, further comprising a covering disposed on an outer surface of the first tubular frame, wherein the covering is configured to inhibit blood flow around the prosthetic heart valve and to promote tissue ingrowth between the prosthetic heart valve and native tissue at an implantation location.
9. The prosthetic heart valve of claim 1, further comprising a covering disposed on an outer surface of the flange, wherein the covering is configured to inhibit blood flow around the prosthetic heart valve and to promote tissue ingrowth between the prosthetic heart valve and native tissue at an implantation location.
10. A prosthetic heart valve comprising: an outer frame comprising a plurality of interconnected wire members, an inflow end portion, and an outflow end portion, wherein the outer frame is movable between a radially collapsed state and a radially expanded state, and wherein the plurality of interconnected wire members deflect relative to each other as the outer frame moves between the radially collapsed state and the radially expanded state;an inner frame disposed within and coupled to the outer frame;a valve member disposed within and coupled to the inner frame, wherein the valve member comprises a plurality of leaflets arranged to form a one-way valve to control blood flow therebetween;one or more actuator members coupled to the plurality of interconnected wire members of the outer frame, wherein the actuator members are configured to facilitate movement of the outer frame between the radially collapsed state and the radially expanded state; anda flange coupled to and extending radially outwardly from the outer frame, wherein the flange comprises a plurality of deflectable petals configured to move between a folded state and an unfolded state, wherein the plurality of deflectable petals comprises a first petal having a first length in the unfolded state and a second petal having a second length in the unfolded state, and wherein the first length is different than the second length.
11. The prosthetic heart valve of claim 10, wherein the flange is coupled to the inflow end portion of the outer frame.
12. The prosthetic heart valve of claim 11, wherein the flange is a first flange, wherein the prosthetic heart valve further comprises a second flange coupled to the outflow end portion of the outer frame.
13. The prosthetic heart valve of claim 12, wherein at least a portion of the first flange extends radially outwardly beyond the second flange.
14. The prosthetic heart valve of claim 10, wherein the flange is a first flange coupled to the outflow end portion of the outer frame, wherein the prosthetic heart valve further comprises a second flange coupled to the inflow end portion of the outer frame, and wherein at least a portion of the first flange extends radially outwardly beyond the second flange.
15. The prosthetic heart valve of claim 10, further comprising an intermediate frame coupled to and extending radially between the outer frame and the inner frame.
16. A prosthetic heart valve comprising: a first frame comprising an interconnected lattice, an inflow end portion, and an outflow end portion, wherein the first frame is movable between a radially collapsed state and a radially expanded state, and wherein the interconnected lattice deflects as the first frame moves between the radially collapsed state and the radially expanded state;a second frame disposed within and coupled to the first frame;a multi-leaflet valve disposed within and coupled to the first frame, wherein the multi-leaflet valve is configured to allow one-way blood flow therethrough;one or more movable rods coupled to the interconnected lattice of the first frame, wherein the one or more movable rods are configured to facilitate movement of the first frame between the radially collapsed state and the radially expanded state; anda flange coupled to and extending radially outwardly from the first frame, wherein the flange comprises a plurality of deflectable petals configured to move between a first state and a second state, wherein the plurality of deflectable petals comprises a first petal having a first length and a second petal having a second length, and wherein the first length is different than the second length.
17. The prosthetic heart valve of claim 16, further comprising a selective locking element coupled to the first frame, and wherein the one or more movable rods comprise multiple points that generate mechanical interference with the selective locking element at various states of radial expansion of the first frame.
18. The prosthetic heart valve of claim 17, wherein the one or more movable rods comprise a threaded portion configured to threadably attach the one or more movable rods to control wires of a delivery apparatus.
19. The prosthetic heart valve of claim 16, wherein the one or more movable rods comprises a first threaded portion configured to engaged a threaded element of the first frame.
20. The prosthetic heart valve of claim 19, wherein the one or more movable rods comprise a second threaded portion configured to threadably attach the one or more movable rods to control wires of a delivery apparatus.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No. 16/143,130, filed Sep. 26, 2018, now U.S. Pat. No. 10,842,620, which is a continuation of U.S. application Ser. No. 15/191,054, filed Jun. 23, 2016, now U.S. Pat. No. 10,092,400, which claims the benefit of U.S. Provisional Application No. 62/183,562, filed Jun. 23, 2015. Each related application is incorporated by reference herein.

US Referenced Citations (510)

Number	Name	Date	Kind
3657744	Ersek	Apr 1972	A
3671979	Moulopoulos	Jun 1972	A
3739402	Cooley et al.	Jun 1973	A
4056854	Boretos et al.	Nov 1977	A
4079468	Liotta et al.	Mar 1978	A
4204283	Bellhouse et al.	May 1980	A
4222126	Boretos et al.	Sep 1980	A
4265694	Boretos et al.	May 1981	A
4339831	Johnson	Jul 1982	A
4340977	Brownlee et al.	Jul 1982	A
4470157	Love	Sep 1984	A
4477930	Totten et al.	Oct 1984	A
4490859	Black et al.	Jan 1985	A
4553545	Maass et al.	Nov 1985	A
4777951	Cribier et al.	Oct 1988	A
4865600	Carpentier et al.	Sep 1989	A
4994077	Dobben	Feb 1991	A
5326371	Love et al.	Jul 1994	A
5332402	Teitelbaum	Jul 1994	A
5370685	Stevens	Dec 1994	A
5415667	Frater	May 1995	A
5545214	Stevens	Aug 1996	A
5554183	Nazari	Sep 1996	A
5554185	Block et al.	Sep 1996	A
5697382	Love et al.	Dec 1997	A
5797951	Mueller	Aug 1998	A
5840081	Andersen et al.	Nov 1998	A
5855601	Bessler et al.	Jan 1999	A
5957949	Leonhardt et al.	Sep 1999	A
6086612	Jansen	Jul 2000	A
6113631	Jansen	Sep 2000	A
6168614	Andersen et al.	Jan 2001	B1
6224626	Steinke	May 2001	B1
6251093	Valley et al.	Jun 2001	B1
6267783	Letendre et al.	Jul 2001	B1
6312465	Griffin et al.	Nov 2001	B1
6358277	Duran	Mar 2002	B1
6440164	DiMatteo et al.	Aug 2002	B1
6458153	Bailey et al.	Oct 2002	B1
6482228	Norred	Nov 2002	B1
6527800	McGuckin, Jr. et al.	Mar 2003	B1
6558396	Inoue	May 2003	B1
6582462	Andersen et al.	Jun 2003	B1
6610088	Gabbay	Aug 2003	B1
6629534	St. Goar et al.	Oct 2003	B1
6652578	Bailey et al.	Nov 2003	B2
6656215	Yanez et al.	Dec 2003	B1
6669720	Pierce	Dec 2003	B1
6676698	McGuckin, Jr. et al.	Jan 2004	B2
6695878	McGuckin, Jr. et al.	Feb 2004	B2
6712836	Berg et al.	Mar 2004	B1
6716207	Farnholtz	Apr 2004	B2
6716230	Whitman	Apr 2004	B2
6729356	Baker et al.	May 2004	B1
6730118	Spenser et al.	May 2004	B2
6730121	Ortiz et al.	May 2004	B2
6733525	Yang et al.	May 2004	B2
6746422	Noriega et al.	Jun 2004	B1
6749560	Konstorum et al.	Jun 2004	B1
6761733	Chobotov et al.	Jul 2004	B2
6767362	Schreck	Jul 2004	B2
6773456	Gordon et al.	Aug 2004	B1
6780200	Jansen	Aug 2004	B2
6790229	Berreklouw	Sep 2004	B1
6790230	Beyersdorf et al.	Sep 2004	B2
6860900	Clerc et al.	Mar 2005	B2
6875231	Anduiza et al.	Apr 2005	B2
6890350	Walak	May 2005	B1
6893460	Spenser et al.	May 2005	B2
6908481	Cribier	Jun 2005	B2
6929659	Pinchuk	Aug 2005	B2
6945994	Austin et al.	Sep 2005	B2
6951571	Srivastava	Oct 2005	B1
7007396	Rudko et al.	Mar 2006	B2
7011681	Vesely	Mar 2006	B2
7018406	Seguin et al.	Mar 2006	B2
7041132	Quijano et al.	May 2006	B2
7090688	Nishtala et al.	Aug 2006	B2
7097658	Oktay	Aug 2006	B2
7141063	White et al.	Nov 2006	B2
7186265	Sharkawy et al.	Mar 2007	B2
7192440	Andreas et al.	Mar 2007	B2
7198646	Figulla et al.	Apr 2007	B2
7201772	Schwammenthal et al.	Apr 2007	B2
7276078	Spenser et al.	Oct 2007	B2
7329278	Seguin et al.	Feb 2008	B2
7381219	Salahieh et al.	Jun 2008	B2
7393360	Spenser et al.	Jul 2008	B2
7429269	Schwammenthal et al.	Sep 2008	B2
7442204	Schwammenthal et al.	Oct 2008	B2
7445631	Salahieh et al.	Nov 2008	B2
7462191	Spenser et al.	Dec 2008	B2
7510575	Spenser et al.	Mar 2009	B2
7524330	Berreklouw	Apr 2009	B2
7553324	Andreas et al.	Jun 2009	B2
7585321	Cribier	Sep 2009	B2
7618446	Andersen et al.	Nov 2009	B2
7621948	Herrmann et al.	Nov 2009	B2
7628805	Spenser et al.	Dec 2009	B2
7748389	Salahieh et al.	Jul 2010	B2
7753949	Lamphere et al.	Jul 2010	B2
7803185	Gabbay	Sep 2010	B2
7806919	Bloom et al.	Oct 2010	B2
7815673	Bloom et al.	Oct 2010	B2
7824443	Salahieh et al.	Nov 2010	B2
7892281	Seguin et al.	Feb 2011	B2
7914569	Nguyen et al.	Mar 2011	B2
7947075	Goetz et al.	May 2011	B2
7959672	Salahieh	Jun 2011	B2
7972378	Tabor et al.	Jul 2011	B2
7981151	Rowe	Jul 2011	B2
7993392	Righini et al.	Aug 2011	B2
7993394	Hariton et al.	Aug 2011	B2
8016877	Seguin et al.	Sep 2011	B2
8048153	Salahieh et al.	Nov 2011	B2
8052750	Tuval et al.	Nov 2011	B2
8070800	Lock et al.	Dec 2011	B2
8070802	Lamphere et al.	Dec 2011	B2
8075615	Eberhardt et al.	Dec 2011	B2
8080054	Rowe	Dec 2011	B2
8092520	Quadri	Jan 2012	B2
8109996	Stacchino et al.	Feb 2012	B2
8118866	Herrmann et al.	Feb 2012	B2
8136218	Millwee et al.	Mar 2012	B2
8137398	Tuval et al.	Mar 2012	B2
8157852	Bloom et al.	Apr 2012	B2
8167934	Styrc et al.	May 2012	B2
8182528	Salahieh et al.	May 2012	B2
8182530	Huber	May 2012	B2
8216301	Bonhoeffer et al.	Jul 2012	B2
8219229	Cao et al.	Jul 2012	B2
8220121	Hendriksen et al.	Jul 2012	B2
8221493	Boyle et al.	Jul 2012	B2
8226707	White	Jul 2012	B2
8226710	Nguyen et al.	Jul 2012	B2
8236045	Benichou et al.	Aug 2012	B2
8246675	Zegdi	Aug 2012	B2
8246678	Salahieh et al.	Aug 2012	B2
8252036	Cartledge et al.	Aug 2012	B2
8252051	Chau et al.	Aug 2012	B2
8252052	Salahieh et al.	Aug 2012	B2
8287584	Salahieh et al.	Oct 2012	B2
8303653	Bonhoeffer et al.	Nov 2012	B2
8313525	Tuval et al.	Nov 2012	B2
8323335	Rowe et al.	Dec 2012	B2
8353953	Giannetti et al.	Jan 2013	B2
8403983	Quadri et al.	Mar 2013	B2
8414644	Quadri et al.	Apr 2013	B2
8414645	Dwork et al.	Apr 2013	B2
8444689	Zhang	May 2013	B2
8449599	Chau et al.	May 2013	B2
8454685	Hariton et al.	Jun 2013	B2
8460368	Taylor et al.	Jun 2013	B2
8470023	Eidenschink et al.	Jun 2013	B2
8475521	Suri et al.	Jul 2013	B2
8475523	Duffy	Jul 2013	B2
8479380	Malewicz et al.	Jul 2013	B2
8486137	Suri et al.	Jul 2013	B2
8491650	Wiemeyer et al.	Jul 2013	B2
8500733	Watson	Aug 2013	B2
8500798	Rowe et al.	Aug 2013	B2
8511244	Holecek et al.	Aug 2013	B2
8512401	Murray, III et al.	Aug 2013	B2
8518096	Nelson	Aug 2013	B2
8518106	Duffy et al.	Aug 2013	B2
8562663	Mearns et al.	Oct 2013	B2
8579963	Tabor	Nov 2013	B2
8579964	Lane et al.	Nov 2013	B2
8579965	Bonhoeffer et al.	Nov 2013	B2
8585755	Chau et al.	Nov 2013	B2
8585756	Bonhoeffer et al.	Nov 2013	B2
8591570	Revuelta et al.	Nov 2013	B2
8597348	Rowe et al.	Dec 2013	B2
8617236	Paul et al.	Dec 2013	B2
8640521	Righini et al.	Feb 2014	B2
8647378	Mews et al.	Feb 2014	B2
8647381	Essinger et al.	Feb 2014	B2
8652145	Maimon et al.	Feb 2014	B2
8652201	Oberti et al.	Feb 2014	B2
8652202	Alon et al.	Feb 2014	B2
8652203	Quadri et al.	Feb 2014	B2
8668733	Haug et al.	Mar 2014	B2
8673000	Tabor et al.	Mar 2014	B2
8673001	Cartledge et al.	Mar 2014	B2
8679174	Ottma et al.	Mar 2014	B2
8679404	Liburd et al.	Mar 2014	B2
8685086	Navia et al.	Apr 2014	B2
8721708	Seguin et al.	May 2014	B2
8721714	Kelley	May 2014	B2
8728154	Alkhatib	May 2014	B2
8728155	Montorfano et al.	May 2014	B2
8740974	Lambrecht et al.	Jun 2014	B2
8740976	Tran et al.	Jun 2014	B2
8747458	Tuval et al.	Jun 2014	B2
8747459	Nguyen et al.	Jun 2014	B2
8747460	Tuval et al.	Jun 2014	B2
8758432	Solem	Jun 2014	B2
8764818	Gregg	Jul 2014	B2
8771344	Tran et al.	Jul 2014	B2
8771345	Tuval et al.	Jul 2014	B2
8771346	Tuval et al.	Jul 2014	B2
8778020	Gregg et al.	Jul 2014	B2
8784337	Voeller et al.	Jul 2014	B2
8784478	Tuval et al.	Jul 2014	B2
8784481	Alkhatib et al.	Jul 2014	B2
8790387	Nguyen et al.	Jul 2014	B2
8795356	Quadri et al.	Aug 2014	B2
8795357	Yohanan et al.	Aug 2014	B2
8808356	Braido et al.	Aug 2014	B2
8828078	Salahieh et al.	Sep 2014	B2
8828079	Thielen et al.	Sep 2014	B2
8834564	Tuval et al.	Sep 2014	B2
8845718	Tuval et al.	Sep 2014	B2
8858620	Salahieh et al.	Oct 2014	B2
8870948	Erzberger et al.	Oct 2014	B1
8870950	Hacohen	Oct 2014	B2
8876893	Dwork et al.	Nov 2014	B2
8876894	Tuval et al.	Nov 2014	B2
8876895	Tuval et al.	Nov 2014	B2
8911455	Quadri et al.	Dec 2014	B2
8926693	Duffy et al.	Jan 2015	B2
8926694	Costello	Jan 2015	B2
8939960	Rosenman et al.	Jan 2015	B2
8945209	Bonyuet et al.	Feb 2015	B2
8951299	Paul et al.	Feb 2015	B2
8961593	Bonhoeffer et al.	Feb 2015	B2
8961595	Alkhatib	Feb 2015	B2
8974524	Yeung et al.	Mar 2015	B2
8979922	Jayasinghe et al.	Mar 2015	B2
8986372	Murry, III et al.	Mar 2015	B2
8986375	Garde et al.	Mar 2015	B2
8992608	Haug et al.	Mar 2015	B2
8998979	Seguin et al.	Apr 2015	B2
8998980	Shipley et al.	Apr 2015	B2
9005273	Salahieh et al.	Apr 2015	B2
9011521	Haug et al.	Apr 2015	B2
9011523	Seguin	Apr 2015	B2
9011524	Eberhardt	Apr 2015	B2
9028545	Taylor	May 2015	B2
9034032	McLean et al.	May 2015	B2
9034033	McLean et al.	May 2015	B2
9039757	McLean et al.	May 2015	B2
9055937	Rowe et al.	Jun 2015	B2
9066801	Kovalsky et al.	Jun 2015	B2
9078749	Lutter et al.	Jul 2015	B2
9078751	Naor	Jul 2015	B2
9084676	Chau et al.	Jul 2015	B2
9125738	Figulla et al.	Sep 2015	B2
9138312	Tuval et al.	Sep 2015	B2
9161834	Taylor et al.	Oct 2015	B2
9173737	Hill et al.	Nov 2015	B2
9180004	Alkhatib	Nov 2015	B2
9186249	Rolando et al.	Nov 2015	B2
9220594	Braido et al.	Dec 2015	B2
9241790	Lane et al.	Jan 2016	B2
9248014	Lane et al.	Feb 2016	B2
9277990	Klima et al.	Mar 2016	B2
9277993	Gamarra et al.	Mar 2016	B2
9289291	Gorman, III et al.	Mar 2016	B2
9289296	Braido et al.	Mar 2016	B2
9295551	Straubinger et al.	Mar 2016	B2
9326815	Watson	May 2016	B2
9331328	Eberhardt et al.	May 2016	B2
9339382	Tabor et al.	May 2016	B2
9351831	Braido et al.	May 2016	B2
9351832	Braido et al.	May 2016	B2
9364321	Alkhatib et al.	Jun 2016	B2
9445897	Bishop et al.	Sep 2016	B2
9456877	Weitzner et al.	Oct 2016	B2
9681968	Goetz et al.	Jun 2017	B2
9700329	Metzger et al.	Jul 2017	B2
9700411	Klima et al.	Jul 2017	B2
9795479	Lim et al.	Oct 2017	B2
9833313	Board et al.	Dec 2017	B2
9861473	Lafontaine	Jan 2018	B2
9861476	Salahieh et al.	Jan 2018	B2
9861477	Backus et al.	Jan 2018	B2
9867698	Kovalsky et al.	Jan 2018	B2
9877830	Lim et al.	Jan 2018	B2
9889029	Li et al.	Feb 2018	B2
9895225	Rolando et al.	Feb 2018	B2
9925045	Creaven et al.	Mar 2018	B2
20020032481	Gabbay	Mar 2002	A1
20020045929	Diaz	Apr 2002	A1
20020052644	Shaolian et al.	May 2002	A1
20020077695	Swanson et al.	Jun 2002	A1
20030105517	White et al.	Jun 2003	A1
20030120331	Chobotov et al.	Jun 2003	A1
20030120333	Ouriel et al.	Jun 2003	A1
20030130729	Paniagua et al.	Jul 2003	A1
20030176914	Rabkin et al.	Sep 2003	A1
20030199971	Tower et al.	Oct 2003	A1
20030220683	Minasian et al.	Nov 2003	A1
20040117009	Cali et al.	Jun 2004	A1
20040133273	Cox	Jul 2004	A1
20040186561	McGuckin et al.	Sep 2004	A1
20040210304	Seguin et al.	Oct 2004	A1
20040210307	Khairkhahan	Oct 2004	A1
20040215325	Penn et al.	Oct 2004	A1
20040225353	McGuckin et al.	Nov 2004	A1
20040236411	Sarac et al.	Nov 2004	A1
20050033398	Seguin	Feb 2005	A1
20050075727	Wheatley	Apr 2005	A1
20050090887	Pryor	Apr 2005	A1
20050096738	Cali et al.	May 2005	A1
20050107872	Mensah et al.	May 2005	A1
20050137682	Justino	Jun 2005	A1
20050137686	Salahieh et al.	Jun 2005	A1
20050137687	Salahieh et al.	Jun 2005	A1
20050137691	Salahieh et al.	Jun 2005	A1
20050137693	Haug et al.	Jun 2005	A1
20050159811	Lane	Jul 2005	A1
20050182486	Gabbay	Aug 2005	A1
20050216079	MaCoviak	Sep 2005	A1
20050234546	Nugent et al.	Oct 2005	A1
20050283231	Haug et al.	Dec 2005	A1
20060020327	Lashinski et al.	Jan 2006	A1
20060052867	Revuelta et al.	Mar 2006	A1
20060058872	Salahieh et al.	Mar 2006	A1
20060095115	Bladillah et al.	May 2006	A1
20060173527	Scherrible	Aug 2006	A1
20060173537	Yang et al.	Aug 2006	A1
20060195183	Navia et al.	Aug 2006	A1
20060212110	Osborne et al.	Sep 2006	A1
20060241745	Solem	Oct 2006	A1
20060259135	Navia et al.	Nov 2006	A1
20060265056	Nguyen et al.	Nov 2006	A1
20060287717	Rowe et al.	Dec 2006	A1
20060293745	Carpentier et al.	Dec 2006	A1
20070010876	Salahieh et al.	Jan 2007	A1
20070043435	Seguin et al.	Feb 2007	A1
20070050021	Johnson	Mar 2007	A1
20070100432	Case et al.	May 2007	A1
20070129794	Realyvasquez	Jun 2007	A1
20070142906	Figulla et al.	Jun 2007	A1
20070213813	Von Segesser et al.	Sep 2007	A1
20070255394	Ryan	Nov 2007	A1
20080009746	Forster et al.	Jan 2008	A1
20080021546	Patz et al.	Jan 2008	A1
20080071366	Tuval et al.	Mar 2008	A1
20080082164	Friedman	Apr 2008	A1
20080082165	Wilson et al.	Apr 2008	A1
20080097581	Shanley	Apr 2008	A1
20080147179	Cai et al.	Jun 2008	A1
20080147183	Styrc	Jun 2008	A1
20080161911	Revuelta et al.	Jul 2008	A1
20080177381	Navia et al.	Jul 2008	A1
20080183273	Mesana et al.	Jul 2008	A1
20080208328	Antocci et al.	Aug 2008	A1
20080228254	Ryan	Sep 2008	A1
20090005863	Goetz et al.	Jan 2009	A1
20090030501	Morris et al.	Jan 2009	A1
20090099653	Suri et al.	Apr 2009	A1
20090138079	Tuval et al.	May 2009	A1
20090171456	Kveen et al.	Jul 2009	A1
20090182413	Burkart et al.	Jul 2009	A1
20090188964	Orlov	Jul 2009	A1
20090270972	Lane	Oct 2009	A1
20090276027	Glynn	Nov 2009	A1
20090276040	Rowe et al.	Nov 2009	A1
20090281618	Hill et al.	Nov 2009	A1
20090287296	Manasse	Nov 2009	A1
20090292350	Eberhardt et al.	Nov 2009	A1
20090306768	Quadri	Dec 2009	A1
20100114305	Kang et al.	May 2010	A1
20100191326	Alkhatib	Jul 2010	A1
20100217382	Chau et al.	Aug 2010	A1
20100249894	Oba et al.	Sep 2010	A1
20100249911	Alkhatib	Sep 2010	A1
20100256723	Murray	Oct 2010	A1
20100305685	Millwee et al.	Dec 2010	A1
20110004296	Lutter et al.	Jan 2011	A1
20110029067	McGuckin, Jr. et al.	Feb 2011	A1
20110208297	Tuval et al.	Aug 2011	A1
20110208298	Tuval et al.	Aug 2011	A1
20110224785	Hacohen	Sep 2011	A1
20110264196	Savage et al.	Oct 2011	A1
20110313515	Quadri et al.	Dec 2011	A1
20120022639	Hacohen et al.	Jan 2012	A1
20120041550	Salahieh et al.	Feb 2012	A1
20120059454	Millwee et al.	Mar 2012	A1
20120078360	Rafiee	Mar 2012	A1
20120101571	Thambar et al.	Apr 2012	A1
20120101572	Kovalsky et al.	Apr 2012	A1
20120123529	Levi et al.	May 2012	A1
20120215303	Quadri et al.	Aug 2012	A1
20120271398	Essinger et al.	Oct 2012	A1
20120290062	McNamara et al.	Nov 2012	A1
20120310328	Olson et al.	Dec 2012	A1
20120323316	Chau et al.	Dec 2012	A1
20130006294	Kashkarov et al.	Jan 2013	A1
20130035759	Gross et al.	Feb 2013	A1
20130046373	Cartledge et al.	Feb 2013	A1
20130053950	Rowe et al.	Feb 2013	A1
20130131788	Quadri et al.	May 2013	A1
20130144378	Quadri et al.	Jun 2013	A1
20130166017	Cartledge et al.	Jun 2013	A1
20130211508	Lane et al.	Aug 2013	A1
20130253635	Straubinger et al.	Sep 2013	A1
20130253642	Brecker	Sep 2013	A1
20130310928	Morriss et al.	Nov 2013	A1
20130331929	Mitra et al.	Dec 2013	A1
20130338766	Hastings et al.	Dec 2013	A1
20130345786	Behan	Dec 2013	A1
20140018912	Delaloye et al.	Jan 2014	A1
20140025163	Padala et al.	Jan 2014	A1
20140039611	Lane et al.	Feb 2014	A1
20140052237	Lane et al.	Feb 2014	A1
20140052242	Revuelta et al.	Feb 2014	A1
20140100651	Kheradvar et al.	Apr 2014	A1
20140100653	Savage et al.	Apr 2014	A1
20140142694	Tabor et al.	May 2014	A1
20140163668	Rafiee	Jun 2014	A1
20140172077	Bruchman et al.	Jun 2014	A1
20140172083	Bruchman et al.	Jun 2014	A1
20140194981	Menk et al.	Jul 2014	A1
20140207231	Hacohen et al.	Jul 2014	A1
20140214153	Ottma et al.	Jul 2014	A1
20140214154	Nguyen et al.	Jul 2014	A1
20140214155	Kelley	Jul 2014	A1
20140214159	Vidlund et al.	Jul 2014	A1
20140214160	Naor	Jul 2014	A1
20140222136	Geist et al.	Aug 2014	A1
20140222139	Nguyen et al.	Aug 2014	A1
20140222142	Kovalsky et al.	Aug 2014	A1
20140222144	Eberhardt et al.	Aug 2014	A1
20140230515	Tuval et al.	Aug 2014	A1
20140236288	Lambrecht et al.	Aug 2014	A1
20140257467	Lane et al.	Sep 2014	A1
20140277390	Ratz et al.	Sep 2014	A1
20140277402	Essinger et al.	Sep 2014	A1
20140277422	Ratz et al.	Sep 2014	A1
20140277427	Ratz et al.	Sep 2014	A1
20140296973	Bergheim et al.	Oct 2014	A1
20140296975	Tegels et al.	Oct 2014	A1
20140303719	Cox et al.	Oct 2014	A1
20140309728	Dehdashtian et al.	Oct 2014	A1
20140309732	Solem	Oct 2014	A1
20140324160	Benichou et al.	Oct 2014	A1
20140324164	Gross et al.	Oct 2014	A1
20140330368	Gloss et al.	Nov 2014	A1
20140330371	Gloss et al.	Nov 2014	A1
20140330372	Weston et al.	Nov 2014	A1
20140336754	Gurskis et al.	Nov 2014	A1
20140343669	Lane et al.	Nov 2014	A1
20140343670	Bakis et al.	Nov 2014	A1
20140343671	Yohanan et al.	Nov 2014	A1
20140350663	Braido et al.	Nov 2014	A1
20140350666	Righini	Nov 2014	A1
20140350668	Delaloye et al.	Nov 2014	A1
20140358223	Rafiee et al.	Dec 2014	A1
20140364939	Deshmukh et al.	Dec 2014	A1
20140364943	Conklin	Dec 2014	A1
20140371842	Marquez et al.	Dec 2014	A1
20140371844	Dale et al.	Dec 2014	A1
20140371845	Tuval et al.	Dec 2014	A1
20140371847	Madrid et al.	Dec 2014	A1
20140371848	Murray, III et al.	Dec 2014	A1
20140379067	Nguyen et al.	Dec 2014	A1
20140379068	Thielen et al.	Dec 2014	A1
20140379077	Tuval et al.	Dec 2014	A1
20150005863	Para	Jan 2015	A1
20150012085	Salahieh et al.	Jan 2015	A1
20150018938	Von Segesser et al.	Jan 2015	A1
20150018944	O'Connell et al.	Jan 2015	A1
20150039083	Rafiee	Feb 2015	A1
20150045880	Hacohen	Feb 2015	A1
20150142103	Vidlund	May 2015	A1
20150148731	Mcnamara et al.	May 2015	A1
20150157457	Hacohen	Jun 2015	A1
20150157458	Thambar et al.	Jun 2015	A1
20150173897	Raanani et al.	Jun 2015	A1
20150196390	Ma et al.	Jul 2015	A1
20150209141	Braido et al.	Jul 2015	A1
20150272737	Dale et al.	Oct 2015	A1
20150297346	Duffy et al.	Oct 2015	A1
20150327994	Morriss et al.	Nov 2015	A1
20150328001	McLean et al.	Nov 2015	A1
20150335429	Morriss et al.	Nov 2015	A1
20150351903	Morriss et al.	Dec 2015	A1
20150351906	Hammer et al.	Dec 2015	A1
20150359629	Ganesan et al.	Dec 2015	A1
20160000591	Lei et al.	Jan 2016	A1
20160030169	Shahriari	Feb 2016	A1
20160030170	Alkhatib et al.	Feb 2016	A1
20160030171	Quijano et al.	Feb 2016	A1
20160038281	Delaloye et al.	Feb 2016	A1
20160074160	Christianson et al.	Mar 2016	A1
20160106537	Christianson et al.	Apr 2016	A1
20160113765	Ganesan et al.	Apr 2016	A1
20160113766	Ganesan et al.	Apr 2016	A1
20160113768	Ganesan et al.	Apr 2016	A1
20160143732	Glimsdale	May 2016	A1
20160158010	Lim et al.	Jun 2016	A1
20160166383	Lim et al.	Jun 2016	A1
20160184097	Lim et al.	Jun 2016	A1
20160199206	Lim et al.	Jul 2016	A1
20160213473	Hacohen et al.	Jul 2016	A1
20160235529	Ma et al.	Aug 2016	A1
20160279386	Dale et al.	Sep 2016	A1
20170128209	Morriss et al.	May 2017	A1
20170216023	Lane et al.	Aug 2017	A1
20170216575	Asleson et al.	Aug 2017	A1
20170258614	Griffin	Sep 2017	A1
20170325954	Perszyk	Nov 2017	A1
20170348096	Anderson	Dec 2017	A1
20170367823	Hariton et al.	Dec 2017	A1
20180055636	Valencia et al.	Mar 2018	A1
20180085218	Eidenschink	Mar 2018	A1
20180110534	Gavala et al.	Apr 2018	A1

Foreign Referenced Citations (102)

Number	Date	Country
2304325	Oct 2000	CA
2827556	Jul 2012	CA
102006052564	Dec 2007	DE
1171059	Jan 2002	EP
1369098	Dec 2003	EP
1259194	Feb 2005	EP
1255510	Apr 2007	EP
1827558	Sep 2007	EP
1239901	Oct 2007	EP
1472996	Sep 2009	EP
1935377	Mar 2010	EP
2238947	Oct 2010	EP
2308425	Apr 2011	EP
2398543	Dec 2011	EP
1281375	Feb 2012	EP
2496182	Sep 2012	EP
2285317	Dec 2012	EP
2566416	Mar 2013	EP
2319458	Apr 2013	EP
2124826	Jul 2014	EP
2750630	Jul 2014	EP
2777617	Sep 2014	EP
2745805	Jun 2015	EP
2749254	Jun 2015	EP
2898858	Jul 2015	EP
1734903	Oct 2015	EP
2967858	Jan 2016	EP
2926766	Feb 2016	EP
2985006	Feb 2016	EP
2168536	Apr 2016	EP
2815725	Apr 2016	EP
2237746	May 2016	EP
2815723	Jul 2016	EP
2262451	May 2017	EP
3184083	Jun 2017	EP
2446915	Jan 2018	EP
3057541	Jan 2018	EP
3037064	Mar 2018	EP
3046511	Mar 2018	EP
3142603	Mar 2018	EP
3294220	Mar 2018	EP
1264471	Feb 1972	GB
1315844	May 1973	GB
2398245	Aug 2004	GB
2002540889	Dec 2002	JP
2008541865	Nov 2008	JP
0061034	Oct 2000	WO
03092554	Nov 2003	WO
2004030569	Apr 2004	WO
2005011534	Feb 2005	WO
2006070372	Jul 2006	WO
2006085225	Aug 2006	WO
2006089236	Aug 2006	WO
2006127765	Nov 2006	WO
2007025028	Mar 2007	WO
2007058857	May 2007	WO
2007123658	Nov 2007	WO
2008013915	Jan 2008	WO
2008070797	Jun 2008	WO
2008103722	Aug 2008	WO
2008125153	Oct 2008	WO
2008150529	Dec 2008	WO
2009026563	Feb 2009	WO
2009033469	Mar 2009	WO
2009045331	Apr 2009	WO
2009053497	Apr 2009	WO
2009091509	Jul 2009	WO
2009094500	Jul 2009	WO
2009134701	Nov 2009	WO
2010005524	Jan 2010	WO
2010008549	Jan 2010	WO
2010022138	Feb 2010	WO
2010037141	Apr 2010	WO
2010040009	Apr 2010	WO
2010057262	May 2010	WO
2011025945	Mar 2011	WO
2011057087	May 2011	WO
2011111047	Sep 2011	WO
2011137531	Nov 2011	WO
2012177942	Dec 2012	WO
2013028387	Feb 2013	WO
2013059747	Apr 2013	WO
2013075215	May 2013	WO
2013120181	Aug 2013	WO
2013175468	Nov 2013	WO
2013192305	Dec 2013	WO
2014018432	Jan 2014	WO
2014099655	Jun 2014	WO
2014110019	Jul 2014	WO
2014110171	Jul 2014	WO
2014121042	Aug 2014	WO
2014139545	Sep 2014	WO
2014145338	Sep 2014	WO
2014149865	Sep 2014	WO
2014163706	Oct 2014	WO
2014164364	Oct 2014	WO
2014194178	Dec 2014	WO
2014204807	Dec 2014	WO
2014205064	Dec 2014	WO
2015077274	May 2015	WO
2015148241	Oct 2015	WO
2016016899	Feb 2016	WO

Non-Patent Literature Citations (10)

Entry
Bavaria, Joseph E. M.D. et al.: “Transcatheter Mitral Valve Implantation: The Future Gold Standard for MR?,” Applicant requests the Examiner to consider this reference to be prior art as of Dec. 2010.
Boudjemline, Younes, et al., “Steps Toward the Percutaneous Replacement of Atrioventricular Valves,” JACC, vol. 46, No. 2, Jul. 19, 2005:360-5.
Fornell, Dave, “Transcatheter Mitral Valve replacement Devices in Development,” Diagnostic and Interventional Cardiology, Dec. 30, 2014, p. 3, <http://www.dicardiology.com/article/transcatheter-mitral-valve-replacement-devices-development>.
Karimi, Houshang, et al., “Percutaneous Valve Therapies,” SIS 2007 Yearbook, Chapter 11, pp. 1-11.
Lutter, Georg, et al., “Off-Pump Transapical Mitral Valve Replacement,” European Journal of Cardio-thoracic Surgery 36 (2009) 124-128, Applicant believes this may have been available as early as Apr. 25, 2009.
Ma, Liang, et al., “Double-Crowned Valved Stents For Off-Pump Mitral Valve Replacement,” European Journal of Cardio-thoracic Surgery 28 (2005) 194-199, Applicant believes this may have been available as early as Aug. 2005.
Mack, Michael M.D., “Advantages and Limitations of Surgical Mitral Valve Replacement; Lessons for the Transcatheter Approach,” Applicant believes this may have been available as early as Jun. 7, 2010. Applicant believes this may have been presented at the Texas Cardiovascular Innovative Ventures (TCIV) Conference in Dallas, TX on Dec. 8, 2010.
NJ350: Vote for Your Favorite New Jersey Innovations, Jun. 27, 2014, http://www.kilmerhouse.com/2014/06/nj350-vote-for-your-favorite-new-jersey-innovations/.
Pluth, James R., M.D., et al., “Aortic and Mitral Valve Replacement with Cloth-Covered Braunwald-Cutter Prosthesis, A Three-Year Follow-up,” The Annals Of Thoracic Surgery, vol. 20, No. 3, Sep. 1975, pp. 239-248.
Spillner, J. et al., “New Sutureless ‘Atrial-Mitral-Valve Prosthesis’ For Minimally Invasive Mitral Valve Therapy,” Textile Research Journal, 2010, in 7 pages, Applicant believes this may have been available as early as Aug. 9, 2010.

Related Publications (1)

	Number	Date	Country
	20210068948 A1	Mar 2021	US

Provisional Applications (1)

	Number	Date	Country
	62183562	Jun 2015	US

Continuations (2)

	Number	Date	Country
Parent	16143130	Sep 2018	US
Child	16949879		US
Parent	15191054	Jun 2016	US
Child	16143130		US

Systems and methods for anchoring and sealing a prosthetic heart valve

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

Field of Search

CPC

International Classifications

Disclaimer

Term Extension

Abstract